Myocarditis - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myocarditis - Pipeline Review, H2 2017, provides an overview of the Myocarditis (Cardiovascular) pipeline landscape. Myocarditis is inflammation of the heart muscle. Myocarditis is an uncommon disorder that is usually caused by viral, bacterial, or fungal infections that reach the heart. Symptoms include chest pain, rapid or abnormal heartbeat, shortness of breath, at rest or during physical activity, fluid retention with swelling of legs, ankles and feet and fatigue. Treatment includes antibiotics, anti-inflammatory medicines to reduce swelling and diuretics to remove excess water from the body. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myocarditis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Myocarditis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Myocarditis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocarditis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I and Preclinical stages are 1 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively. Myocarditis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Myocarditis (Cardiovascular). - The pipeline guide reviews pipeline therapeutics for Myocarditis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Myocarditis (Cardiovascular) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Myocarditis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Myocarditis (Cardiovascular) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Myocarditis (Cardiovascular). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Myocarditis (Cardiovascular) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Myocarditis - Overview Myocarditis - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Myocarditis - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Myocarditis - Companies Involved in Therapeutics Development CEL-SCI Corp GlaxoSmithKline Plc Swedish Orphan Biovitrum AB Myocarditis - Drug Profiles anakinra - Drug Profile Product Description Mechanism Of Action R&D Progress CEL-1000 - Drug Profile Product Description Mechanism Of Action R&D Progress Cellular Immunotherapy to Target Flt3L for Autoimmune Myocarditis - Drug Profile Product Description Mechanism Of Action R&D Progress chagas disease vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress OBR-5340 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit Coxsackievirus B3 3C Protease for Myocarditis - Drug Profile Product Description Mechanism Of Action R&D Progress VY-OZ - Drug Profile Product Description Mechanism Of Action R&D Progress Myocarditis - Dormant Projects Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Myocarditis, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Myocarditis - Pipeline by CEL-SCI Corp, H2 2017 Myocarditis - Pipeline by GlaxoSmithKline Plc, H2 2017 Myocarditis - Pipeline by Swedish Orphan Biovitrum AB, H2 2017 Myocarditis - Dormant Projects, H2 2017
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.